CD8A and cancer: Even though the early in vivo studies on the NOTAM mouse carrying ITAM mutant FcRγ indicated the ITAM-dependence of in vivo cytotoxicity, uptake of immune complexes, and the cross presentation of antigens in dendritic cells (17, 18), recent papers revealed that daratumumab-induced cancer cell death (after blocking FcγRIIB) and the splenic dendritic cell-mediated activation of CD4- and CD8-positive T cells occur in an FcRγ ITAM-independent manner (19, 20).